Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease

NCT00165737 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00165737
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00165737 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2003
Completion date
June 30, 2006
Enrollment
974 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, vascular